Skip to main content
Top
Published in: BMC Geriatrics 1/2010

Open Access 01-08-2010 | Meeting abstract

B-type natriuretic peptide (NT-proBNP) and thyroid function: study in elderly subjects

Authors: S Mastroianni, A Grembiale, E Succurro, M Lugarà, F Iorio, V Caruso, S Cufone, E Pedace, M Ruffo, C Cloro, F Arturi

Published in: BMC Geriatrics | Special Issue 1/2010

Login to get access

Excerpt

B-type natriuretic peptide (NT-proBNP) is a cardiac neurohormone that is secreted from the left ventricle in response to volume and pressure overload as occurs in patients with congestive heart failure. NT-proBNP has now become a useful tool in the diagnosis of congestive heart failure and in the management of patients with acute dyspnea. In recent years, several studies showed that NT-proBNP levels may be influenced by thyroid diseases. However, there aren’t data on the elderly population, a group of patients in whom the incidence of both thyroid diseases and heart failure is frequent ,. The aim of this study was to assess the levels of NT-proBNP in a group of elderly patients with dyspnea and thyroid disease and without congestive heart failure. …
Metadata
Title
B-type natriuretic peptide (NT-proBNP) and thyroid function: study in elderly subjects
Authors
S Mastroianni
A Grembiale
E Succurro
M Lugarà
F Iorio
V Caruso
S Cufone
E Pedace
M Ruffo
C Cloro
F Arturi
Publication date
01-08-2010
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue Special Issue 1/2010
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/1471-2318-10-S1-A85

Other articles of this Special Issue 1/2010

BMC Geriatrics 1/2010 Go to the issue

Lecture presentation

Genetics of longevity

Lecture presentation

Anesthetic agents and elderly

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine